Workshop: Finding the balance in life-course vaccination

Event
29 Sep 2016
Gastein – Austria / European Health Forum Gastein (EHFG) 2016
ECDC

The main objectives of the session were to: raise awareness about the value and opportunities of life-course vaccination, build understanding of the challenges faced at decision-making level to assess such a shift, discuss the evidence necessary to help prioritising vaccinations across age groups, prompt reflection on relevant ways forward and action at EU and national level.

Scope and purpose:

The projected changes to the EU's demographic structure call for a need to rethink sustainable ways of investing in health, while also ensuring equitable access across all age and social groups. Vaccination can provide a fundamental contribution, averting preventable diseases that occur in individuals of all
ages, and more so with an ageing population. This workshop was expected to feature and prompt reflection on the value that a life-course
approach to vaccination can bring to public health in Europe today. It also shed light on the challenges faced by healthcare systems in making this
happen, particularly to prioritise vaccines across different age groups.

Speakers:

Wolfgang Philipp - Deputy Head of Unit, DG SANTE (C3),
European Commission

Lucia Pastore Celentano - Head of the Vaccine Preventable Disease
Programme, ECDC

Gaetan Gavazzi - Geriatrics Professor, University
Hospital of Grenoble, France

Mary Ramsay - Head of Immunisation, Public Health
England, UK

Marianne Donker - Deputy Director General for Health and
Director for Public Health, Ministry of Health, Welfare and Sport, the
Netherlands

Chair:

Andrea Ammon - Acting Director, ECDC

Registration: For more information visit the website of the EHFG: http://www.ehfg.org/registration.html.​

See all updates on immunisation

Data

Evidence of the safety of the 9vHPV vaccine

Table -

Data

Evidence of the safety of the HPV vaccine in HIV-infected men and women

Table -

Data

Evidence of the efficacy of the HPV vaccines in males

Table -

Data

Evidence of the safety of the HPV vaccines in males

Table -

Data

Evidence of the immunogenicity of the 9vHPV vaccine

Table -